HIV/AIDS Vaccine

First AIDS vaccine tested in Africa generates low immune response

Published in Vaccine Weekly, May 7th, 2003

by Maria G. Essig, MS, ELS, senior medical writer - A preventive AIDS vaccine containing HIV-1 clade B (env and gag-pro) antigens delivered by a canarypox vector elicited a weak but detectable immune response in a significant number of HIV-negative patients, according to a report in the Journal of Infectious Diseases.

Huyen Cao at the California Department of Health Services in the United States and an international team of researchers involved in the HIV Network for Prevention Trials conducted the first preventive AIDS vaccine trial in Africa. The study involved 40 HIV-negative volunteers who received either the canaraypox/HIV-1 clade B vaccine...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2003-05-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry